BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...

WuXi Apptec will sell its Advanced Technologies unit to the US private equity firm Altaris for an undisclosed amount, a ...

A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...

The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the ...

The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...

Amgen, Eli Lilly and UCB sued the federal government, claiming that several STD clinics getting drug discounts under the ...

The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals, but included boxed safety ...

J&J partners with Kaken on STAT6 program, getting rights to KP-723 oral inhibitor. Kaken receives $30M upfront, potential $1.2B in milestone payments after Phase 1.

Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

Bristol Myers Squibb's Sotyktu succeeds in Phase 3 psoriatic arthritis trials, as company leads TYK2 race against Takeda & ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...

Generic drug firm Viatris announced Monday that one of its India-based manufacturing facilities has been placed on import ...